This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


The Safety of Olanzapine in Adolescents With Schizophrenia or Bipolar I Disorder: A Pooled Analysis of 4 Clinical Trials

Ludmila A. Kryzhanovskaya, M.D., Ph.D.; Carol K. Robertson-Plouch, D.V.M.; Wen Xu, Ph.D.; Janice L. Carlson, Ph.D.; Karen M. Merida, B.S.; and Ralf W. Dittmann, M.D., Ph.D.

Published: February 16, 2009

Article Abstract
‘ ‹’ ‹

Objective: To describe the safety of olanzapine treatment in adolescents (aged 13­17 years) with schizophrenia or bipolar I disorder, and to compare these data with those of olanzapine-treated adults.

Data Sources and Study Selection: Placebo-controlled database, adolescents: acute phase of 2 double-blind, placebo-controlled trials (3­6 weeks; olanzapine, N=179, mean age=15.5 years; placebo, N=89, mean age=15.7 years); overall adolescent olanzapine exposure database, adolescents: 4 trials (e.g., the 2 aforementioned studies, each with a 26-week open-label extension phase, and 2 open-label, 4.5- and 24-week trials; N=454, mean age=15.9 years); and adult database: 84 clinical trials of up to 32 weeks.

Data Synthesis: The mean daily dosage of olanzapine was 10.6 mg/day (exposure=48,946 patient days). In the overall adolescent olanzapine exposure database, the most common adverse events included increased weight (31.7%), somnolence (19.8%), and increased appetite (17.4%). In up to 32 weeks of treatment, when compared with adults, adolescents from the overall adolescent olanzapine exposure database gained statistically significantly more weight (7.4 kg vs. 3.2 kg, p<.001); statistically significantly more adolescents gained ≥7% of their baseline weight (65.1% vs. 35.6%, p<.001). Adolescents experienced statistically significant within-group baseline-to-endpoint changes in fasting glucose (p<.001), total cholesterol (p=.002), triglycerides (p=.007), and alanine aminotransferase (p<.001). Two patients from the overall adolescent olanzapine exposure database (0.4%) attempted suicide; 13 (2.9%) had suicidal ideation. In the placebo-controlled database, adolescents had statistically significant baseline-to-endpoint increases in prolactin (11.4 micrograms/L, p<.001); 47.4% had high prolactin levels.

Conclusion: The types of adverse events in olanzapine-treated adolescents appear to be similar to those of adults. The magnitude and incidence of weight and prolactin changes were greater in adolescents.

‘ ‹’ ‹’ ‹’ ‹’ ‹

Volume: 70

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF